This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentMaterialsVideosLet's connectLet's ConnectPfizer medical information

Menu

Close

About CRESEMBA®About CRESEMBA®Meet CRESEMBA®CRESEMBA® in the ICUCRESEMBA® in ActionEfficacy EfficacyInvasive AspergillosisEfficacyGuidelines MucormycosisEfficacyGuidelinesSafetySafetyTolerabilityInvasive AspergillosisMucormycosis Safety ProfileSafety ProfileDosingDosingSimple DosingLinear PKs, Low Variability and TDMPractical ConsiderationsReal-world DataReal-world DataReal-world EffectivenessReal-world SafetyResourcesResourcesSummary of Prescribing InformationEventsMaterialsVideos

A favourable PK profile1–4

CRESEMBA® offers linear and predictable PKs, and therapeutic drug monitoring is not routinely recommended1–5

  

Unlike other azoles, CRESEMBA® has a linear PK profile and low inter- and intra-patient variability.1–4,a Furthermore, the absorption of oral CRESEMBA® is unaffected by food or mucositis.1,6

  

CRESEMBA® has good tissue penetration, allowing maintenance of therapeutic concentrations in the body for a long period of time,7,8 with predictable PKs for reliable treatment when patients need it most.1,2

  

With both IV and oral formulations, the long half-life (56–104 hours) of CRESEMBA® allows for convenient once-daily maintenance dosing.1,3 Therapeutic drug monitoring may be needed in some cases but is not routinely recommended4,5 – helping to avoid inadequate exposure and facilitate long-term treatment at home.9,10

  

a. Up to 600 mg/day.1; PK, pharmacokinetic.

  

Prescribing Information:
CRESEMBA® (isavuconazole)

References:

Adapted from Local Product Document of CRESEMBA® (Isavuconazole) version LPDCRE052021.Kaindl T et al. J Antimicrob Chemother 2019;74:761–767.Natesan SK and Chandrasekar PH. Infect Drug Resist 2016;9:291–300.Andes D et al. Antimicrob Agents Chemother 2018;62(7).Desai AV et al. Antimicrob Agents Chemother 2017;61(12).Kovanda LL et al. Antimicrob Agents Chemother 2017;61(6).Schmitt-Hoffmann A et al. Antimicrob Agents Chemother 2006;50(1):279–285.Ledoux MP et al. J Mycol Med 2018;28(1):15–22.Viljoen FP et al. Med Tech SA 2016;30(1):30–35.Sleeper R et al. Challenges to Achieving Optimal Therapeutic Drug Monitoring Setting. 2010. Available at: https://www.hmpgloballearningnetwork.com/site/altc/content/challenges-achieving-optimal-therapeutic-drug-monitoring-ltc-setting. Accessed May 2022.

PP-CRB-IND-0472 July 2022

  

Dosing CRESEMBA® IV reconstitution, dilution and administration Watch Video IV administration leaflet View Leaflet
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-CRB-IND-0472

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

Copyright © 2023 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
For the use only of Registered medical practitioners* or a Hospital or a Laboratory

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.

 

If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-DOL-IND-0251 18 JAN 2023Yes No
You are now leaving PfizerPro website
​
​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?
PP-DOL-IND-0251 18 JAN 2023